EMD Serono, a subsidiary of Merck KGaA, and Open Monoclonal Technology, Inc. (OMT) have expanded their collaboration; EMD Serono will make an upfront payment to secure unlimited access to OMT’s OmniRat platform, as well as success-based development milestones and royalties. Financial details were not disclosed.   “The expansion of our collaboration with OMT is reflective of its strong quality and the significant progress we’ve made together over the last 15 months,” said Dr. Annalisa...